US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,433.04

-10.7144-0.74%

Number of Gainers:11

Number of Losers:9

Number of Flat:- -

PE:- -

High:1,448.24

Open:1,447.71

Low:1,424.24

Close:1,443.75

Loading ...

FDA Places Hold on BioNTech’s Malaria Vaccine Trial

Moderna CEO Stephane Bancel Reports Open Market Purchase of 102,821 Shares of Common Stock at Avg Price of 31.04/Share on March 3 - SEC Filing

THOMSON REUTERS

BioNTech - FDA Placed Clinical Hold On Ind Application & Related Phase I/IIA Clinical Trial (Nct06069544)

BioNTech reports FDA clinical hold on Phase I/IIa trial of BNT165e

Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

THOMSON REUTERS

Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

Healthcare Stocks Avoid Tariff Damage. There Are Other Problems. -- Barrons.com

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market

Simply Wall St.

Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates

Simply Wall St.

Pfizer could use existing U.S. production to counter tariff hit, Reuters reports

Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025

Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug

MT Newswires Live

1 Stock Down 43% That Looks Too Cheap to Ignore

Lakeland Fire + Safety to Attend the 37th Annual Roth Conference

Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4568/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1433.0376,"timestamp":1741809599999,"preClose":1443.752,"halted":0,"volume":85939907,"delay":0,"changeRate":-0.007421,"change":-10.714355,"pbRate":4.031245,"amount":4993423309.826061,"amplitude":0.016623,"prevYearClose":1274.8187,"fiveDayClose":1470.1858,"twentyDayClose":1369.0735,"turnoverRate":0.005557,"marketCap":1180948709760.5,"floatMarketCap":1160519847879.5,"peRate":32.193039},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1448.2382,"amplitude":0.016623,"preClose":1443.752,"low":1424.2384,"pbRate":"4.031245","latestPrice":1433.0376,"volume":85939907,"delay":0,"open":1447.7053,"prevYearClose":1274.8187,"prevWeekClose":1480.0557,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1470.1858,"twentyDayClose":1369.0735,"sixtyDayClose":1282.6448,"secType":"PLATE","market":"US","turnoverRate":0.005557,"peRate":32.193039,"marketCap":1180948709760.5,"floatMarketCap":1160519847879.5,"timestamp":1741809599999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":11,"down":9,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517981030","title":"FDA Places Hold on BioNTech’s Malaria Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517981030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517981030?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:38","pubTimestamp":1741124335,"startTime":"0","endTime":"0","summary":"BioNTech SE ( ($BNTX) ) has issued an update. The U.S. Food and Drug Administration (FDA) has placed a clinical hold on BioNTech SE’s Investigation...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fda-places-hold-on-biontechs-malaria-vaccine-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fda-places-hold-on-biontechs-malaria-vaccine-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4568","BK4139","BK4548","BK4585","BK4588","BNTX","BK4551"],"gpt_icon":0},{"id":"2517981392","title":"Moderna CEO Stephane Bancel Reports Open Market Purchase of 102,821 Shares of Common Stock at Avg Price of 31.04/Share on March 3 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517981392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517981392?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:30","pubTimestamp":1741123817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4501","BK4532","BK4533","BK4548","BK4585","BK4534","BK4139","BK4588","MRNA","BK4568","BK4551"],"gpt_icon":0},{"id":"2517764989","title":"BioNTech - FDA Placed Clinical Hold On Ind Application & Related Phase I/IIA Clinical Trial (Nct06069544)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517764989","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517764989?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:24","pubTimestamp":1741123460,"startTime":"0","endTime":"0","summary":"March 4 (Reuters) - BioNTech SE <22UAy.DE>::*BIONTECH- FDA PLACED CLINICAL HOLD ON IND APPLICATION & RELATED PHASE I/IIA CLINICAL TRIAL (NCT06069544) EVALUATING SAFETY,EFFICACY OF BNT165E*BIONTECH SE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nRSDbhmN94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4139","BK4568","BK4585","BK4551","BK4588","BK4548","BK4535"],"gpt_icon":0},{"id":"2517099989","title":"BioNTech reports FDA clinical hold on Phase I/IIa trial of BNT165e","url":"https://stock-news.laohu8.com/highlight/detail?id=2517099989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517099989?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:17","pubTimestamp":1741123055,"startTime":"0","endTime":"0","summary":"In a regulatory filing, BioNTech (BNTX) disclosed that the U.S. Food and Drug Administration has informed BioNTech SE that it has placed a clinical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biontech-reports-fda-clinical-hold-on-phase-i-iia-trial-of-bnt165e?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biontech-reports-fda-clinical-hold-on-phase-i-iia-trial-of-bnt165e?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4568","BK4139","BK4548","BK4585","BK4588","BNTX","BK4551"],"gpt_icon":0},{"id":"2517989931","title":"Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations","url":"https://stock-news.laohu8.com/highlight/detail?id=2517989931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517989931?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:15","pubTimestamp":1741122902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA795KCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683348.USD","LU2468319806.SGD","LU1162221912.USD","LU1244550221.USD","BK4534","LU0795875086.SGD","JNJ","LU1221951046.USD","LU1914381329.SGD","BK4585","LU1894683264.USD","LU1585245621.USD","LU2430703251.USD","LU0058720904.USD","LU0345770308.USD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU0345769128.USD","IE00B4R5TH58.HKD","BK4568","LU0912757837.SGD","LU1506573853.SGD","LU0203345920.USD","LU0466842654.USD","LU1244550577.SGD","LU1057294990.SGD","LU2592432038.USD","IE00BVYPNW00.USD","LU0640476718.USD","LU1023059063.AUD","LU1066053197.SGD","LU0289739699.SGD","IE00B42XCP33.USD","LU1196500208.SGD","BK4532","LU1280957306.USD","IE00BDGV0183.EUR","LU1061106388.HKD","LU2430703178.SGD","BK4592","LU1066051811.HKD","SG9999002224.SGD","LU1066051225.USD","BK4588","LU2505996681.GBP","LU0098860793.USD","IE00B1BXHZ80.USD","LU2129689431.USD","IE0034235303.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2517989288","title":"Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations","url":"https://stock-news.laohu8.com/highlight/detail?id=2517989288","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517989288?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:15","pubTimestamp":1741122900,"startTime":"0","endTime":"0","summary":"Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. \"Today’s announcement reflects the deep bench of talent within Johnson & Johnson as well as our commitment to fostering career paths for leaders within the Company,\" said Mr. Wolk, \"Darren’s depth and breadth of experience across Johnson & Johnson provides a strong foundation for his new role engaging with analysts and investors and helping them understand our long-term strategy, governance and compelling value proposition.\". Mr. Snellgrove joined Johnson & Johnson in 1999. He holds a bachelor’s honors degree in economics and philosophy from Southampton University in England, and an MBA from Villanova University.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-announces-darren-snellgrove-211500922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","IE00BDGV0183.EUR","LU0640476718.USD","IE00BVYPNV92.GBP","IE0002270589.USD","BK4559","LU2089984988.USD","BK4588","LU1430594728.SGD","IE0009355771.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","LU1894683348.USD","LU1267930813.SGD","LU1935042991.SGD","JNJ","LU1929549753.HKD","IE00BSNM7G36.USD","LU1057294990.SGD","IE000M9KFDE8.USD","LU1244550577.SGD","IE00B4R5TH58.HKD","LU0098860793.USD","LU2430703251.USD","LU0345769128.USD","LU1221951046.USD","BK4504","LU1221951129.SGD","LU1032955483.USD","LU0345770993.USD","LU1066053197.SGD","LU1244550221.USD","IE00BVYPNW00.USD","LU0114720955.EUR","LU1674673428.USD","LU0203345920.USD","IE0034235303.USD","LU1059921491.USD","LU1778281490.HKD","BK4532","LU2129689431.USD","IE00B42XCP33.USD","LU2505996681.GBP","BK4533","LU1061106388.HKD","LU0289739699.SGD","LU1914381329.SGD","BK4568","LU0320765646.SGD","LU1066051498.USD"],"gpt_icon":0},{"id":"2517033607","title":"Healthcare Stocks Avoid Tariff Damage. There Are Other Problems. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2517033607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517033607?lang=en_us&edition=fundamental","pubTime":"2025-03-05 02:41","pubTimestamp":1741113660,"startTime":"0","endTime":"0","summary":"The Trump administration's new tariffs on Canada and Mexico, and higher levies on China, don't seem likely to have a major impact on health stocks, but investors in the sector shouldn't be breathing easy.While drugmakers, medical-device manufacturers, and companies that make scientific tools have far-flung manufacturing networks, those networks for the most part don't rely heavily on either Canada or Mexico.The exception is medical-device makers, some of which do have significant factories in Mexico. Large medical-device stocks were down slightly Tuesday, while some smaller medical-device makers were down more sharply. The iShares U.S. Medical Devices exchange-traded fund, which tracks the companies, fell 1.5%.For the sector at large, though, the new tariffs simply don't top the list of big problems. The Health Care Select Sector SPDR ETF, which tracks healthcare stocks, was down just 0.6% Tuesday, while the S&P 500 was down more than 1%.Among the medical device companies that saw the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALGN","LU1057294990.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","LU1023059063.AUD","SGXZ57979304.SGD","BK4585","BK4533","LU0170899867.USD","LU0868494617.USD","LU0122379950.USD","IE0002270589.USD","LU0306806265.USD","IE00B19Z3B42.SGD","LU1917777945.USD","BK4581","SG9999013999.USD","LU2023250843.SGD","HCSG","LU0225771236.USD","LU1066053197.SGD","LU0058720904.USD","LU1894683264.USD","LU0289739699.SGD","BK4568","SG9999001176.USD","IE00BBT3K403.USD","LU1066051498.USD","BK4592","BK4588","IE00BLSP4452.SGD","SG9999002224.SGD","LU2023250504.SGD","BK4534","SG9999003800.SGD","LU0306807586.USD","BK4599","LU0234572021.USD","LU0456855351.SGD","LU0321505868.SGD","LU2106854487.HKD","SG9999011175.SGD","IE00BLSP4239.USD","LU0225284248.USD","SG9999001176.SGD","LU1894683348.USD","IE00B19Z3581.USD","BK4550"],"gpt_icon":1},{"id":"2517398310","title":"Pharmaceutical Stocks Hit New Highs Amid Market Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2517398310","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517398310?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:34","pubTimestamp":1741109640,"startTime":"0","endTime":"0","summary":"The stock market has a way of proving the masses wrong.After all the chatter about the new administration’s potentially adverse impact on pharmaceutical stocks and related industries, the broader health care sector is leading the charge in 2025.Following the latest market volatility, the S&P 500 is now in negative territory on the year. It’s somewhat surprising to peak behind the curtain and see that 9 of 11 S&P sectors remain green.The price action in the stock market has been fast and furious as investors repositioned their portfolios for the new year. Sector rotation has been on full display, with institutions foregoing growth and technology positions and shifting to more defensive areas like staples, health care and utilities.Historical research studies suggest that approximately half of a stock’s price appreciation is due to its industry grouping. In fact, the top 50% of Zacks Ranked Industries","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharmaceutical-stocks-hit-highs-amid-173400932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","BK4550","IE00BKVL7J92.USD","BK4585","IE00B19Z3581.USD","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","IE00B3T34201.USD","LU2089984988.USD","LU0320765992.SGD","LU1839511570.USD","LU0058720904.USD","LU1066053197.SGD","BK4588","LU1066051498.USD","IE00BSNM7G36.USD","LU2087621335.USD","LU1571399168.USD","BK4566","IE0002270589.USD","BK4578","BK4139","GILD","BK4532","BK4568","BK4583","LU0109394709.USD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU1585245621.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2517607360","title":"Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2517607360","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517607360?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:30","pubTimestamp":1741109451,"startTime":"0","endTime":"0","summary":"Abbott Laboratories recently experienced a 20% price increase over the last quarter. This uptick coincides with several noteworthy developments, including Abbott's collaboration with Cadrenal Therapeutics for the TECH-LVAD trial, which could enhance its footprint in the growing LVAD market valued at $1.1 billion in 2023. The alliance leverages Abbott's advanced HeartMate 3 technology. Additionally, Abbott's strong financial performance, with Q4 2024 results showing substantial growth in sales and net income, may have bolstered investor confidence. The declaration of a quarterly dividend, marking consistent dividends since 1924, further signals stability. Despite market volatility due to tariffs impacting other sectors and companies like Target and Best Buy, Abbott's share buyback program and positive earnings guidance for 2025 reinforced its position. While broader market indices saw declines amid these economic concerns, Abbott's strategic moves and solid financials seemed to counterb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbott-laboratories-nyse-abt-partners-173051288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0034390439.USD","BK4139","LU1061106388.HKD","IE00B4R5TH58.HKD","LU1721429402.USD","LU2237957811.SGD","LENZ","ABT","IE00B2B36J28.USD","LU1057294990.SGD","LU2089984988.USD","LU2133065610.SGD","BK4533","LU1914381329.SGD","BK4581","IE00BFTCPJ56.SGD","IE0002141913.USD","SG9999002224.SGD","LU1691799644.USD","LU0170899867.USD","LU2112291526.USD","BK4566","BK4588","TECH","LU2237957902.USD","BK4585","IE00B64QTZ34.USD","SG9999002232.USD","LU0266013472.USD","SG9999004303.SGD","LU1023059063.AUD","BK4592","BK4568","SGXZ23171101.USD","LU0122379950.USD","BK4082","LU1989763427.SGD","LU1989763690.USD","IE00B19Z6F94.USD","LU2468319806.SGD","BK4121","IE0009355771.USD","NYSE","LU0234572021.USD","LU1721429741.USD","BK4504","LU0868494617.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2517817604","title":"Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517817604","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517817604?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:08","pubTimestamp":1741108082,"startTime":"0","endTime":"0","summary":"As the U.S. market grapples with the impact of newly imposed tariffs and a broad-based sell-off, investors are keenly assessing opportunities that may arise from these turbulent conditions. In such an environment, identifying stocks that appear to be undervalued based on intrinsic estimates can provide potential avenues for investment, as they might offer resilience against broader economic challenges.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Gilead Sciences shows potential as an undervalued stock based on cash flows, trading at US$115.99, significantly below its estimated fair value of US$228.07. Despite high debt levels and a current profit margin dip to 1.7%, earnings are forecasted to grow significantly by 23.6% annually over the next three years, outpacing the broader U.S. market's growth expectations of 14%. Recent regulatory advancements for key products like lenacapavir may bolster future cash flows.Overview: Intuit Inc. offers financial management, co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-gilead-sciences-2-more-170802498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823416689.USD","IE00B19Z3581.USD","LU2237443895.HKD","LU1585245621.USD","GILD","LU1839511570.USD","LU2087621335.USD","LU0256863811.USD","BC","LU0672654240.SGD","LU0114720955.EUR","LU1430594728.SGD","DFS","INTU","IE00BZ1G4Q59.USD","SMWB","LU2237443465.HKD","BK4533","LU0689472784.USD","IE00BFTCPJ56.SGD","LU1093756168.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","BK4139","LU0466842654.USD","LU2237443549.SGD","LU1868837136.USD","SGXZ99366536.SGD","LU1291159041.SGD","LU1127390331.HKD","LU0128526141.USD","LU1791807156.HKD","BK4516","JBTM","LU1814569148.SGD","LU1280957306.USD","LU2237438978.USD","LU0471298694.HKD","LLY","SG9999014898.SGD","SSB","BK4568","SG9999018865.SGD","IE00B4R5TH58.HKD","LU0079474960.USD","BK4581","LU1988902786.USD","GB00BDT5M118.USD","WK","BK4578","LU0820561818.USD"],"gpt_icon":1},{"id":"2516772806","title":"Pfizer could use existing U.S. production to counter tariff hit, Reuters reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2516772806","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516772806?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:41","pubTimestamp":1741099281,"startTime":"0","endTime":"0","summary":"Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous tariff...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pfizer-could-use-existing-u-s-production-to-counter-tariff-hit-reuters-reports?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pfizer-could-use-existing-u-s-production-to-counter-tariff-hit-reuters-reports?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1894683348.USD","BK4592","LU0170899867.USD","LU0321505439.SGD","LU0456855351.SGD","PFE","IE00B19Z3B42.SGD","BK4534","IE0002270589.USD","LU0321505868.SGD","LU0306806265.USD","BK4533","SG9999001176.SGD","IE00BBT3K403.USD","BK4581","BK4599","BK4007","SG9999002232.USD","SG9999011175.SGD","BK4550","LU0225771236.USD","LU0234572021.USD","SG9999001176.USD","LU1883839398.USD","LU1057294990.SGD","LU0225284248.USD","LU0985481810.HKD","IE00B19Z3581.USD","SG9999013999.USD","SG9999002224.SGD","LU1023059063.AUD","LU0122379950.USD","LU1066051498.USD","BK4585","LU0058720904.USD","BK4588","SGXZ57979304.SGD","IE00BLSP4452.SGD","BK4568","SG9999003800.SGD","LU0289739699.SGD","LU0868494617.USD","LU1894683264.USD","LU1066053197.SGD","IE00BLSP4239.USD","IE000M9KFDE8.USD","LU0306807586.USD"],"gpt_icon":0},{"id":"2516674780","title":"Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674780","media":"NewMediaWire","labels":["conferences","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674780?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"Mpox remains a global public health crisis in 2025, with Clade 1b exhibiting higher transmissibility and severity than Clade 2.The Democratic Republic of the Congo  is the epicenter, with over 60,000 suspected cases and 1,300 deaths in 2024 alone.GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as  a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/registration-now-open-tribe-publics-140000126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNTX","BK4139","BK4568","BK4585","R","BK4551","GOVX","BK4588","BK4022","GOVXW","BK4548","BK4535","BK4232"],"gpt_icon":0},{"id":"2516679026","title":"Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516679026","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516679026?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:47","pubTimestamp":1741096056,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics  said Tuesday it has signed a collaboration agreement with Abbott  to support a trial of its tecarfarin anticoagulation and hemocompatibility with left ventricular assist devices.Financial terms were not disclosed.Under the terms of the agreement, Abbott will support Cadrenal on the planning and execution of the trial to evaluate the efficacy and safety of tecarfarin in patients with left ventricular assist devices.Abbott will also share insights from recent trials and will support Cadrenal with trial design, site identification, trial awareness, and expertise.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0868494617.USD","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4568","LU0170899867.USD","LU0266013472.USD","SG9999002224.SGD","SG9999004303.SGD","IE00BFTCPJ56.SGD","BK4581","LU1989763690.USD","CVKD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2112291526.USD","BK4585","LU1061106388.HKD","LU2468319806.SGD","LU1057294990.SGD","LU1989763427.SGD","BK4504","ABT","LU2133065610.SGD","LU1721429402.USD","LU1691799644.USD","IE0009355771.USD","BK4592","SGXZ23171101.USD","LU1721429741.USD","BK4566","SG9999002232.USD","LENZ","LU0234572021.USD","LU2237957902.USD","LU1023059063.AUD","BK4082","BK4588","BK4007","ABT.AU","BK4139","LU1914381329.SGD","LU2237957811.SGD","BK4533","LU2089984988.USD"],"gpt_icon":0},{"id":"2516901677","title":"1 Stock Down 43% That Looks Too Cheap to Ignore","url":"https://stock-news.laohu8.com/highlight/detail?id=2516901677","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516901677?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:45","pubTimestamp":1741095900,"startTime":"0","endTime":"0","summary":"After all this time, Pfizer's coronavirus portfolio is still performing relatively well.The drumaker has an impressive pipeline that should lead to plenty of brand-new drugs.The stock's valuation looks attractive, and it offers a generous dividend yield.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/04/1-stock-down-43-that-looks-too-cheap-to-ignore/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4007","LU0225284248.USD","SG9999011175.SGD","BK4533","LU0868494617.USD","LU0289739699.SGD","LU1883839398.USD","LU0225771236.USD","SG9999002224.SGD","LU0058720904.USD","BK4585","IE000M9KFDE8.USD","LU1066053197.SGD","LU1023059063.AUD","PFE","IE00BBT3K403.USD","IE00B19Z3B42.SGD","LU0321505868.SGD","SG9999003800.SGD","LU0456855351.SGD","SG9999013999.USD","BK4599","IE0002270589.USD","LU0306807586.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","SG9999002232.USD","LU0985481810.HKD","BK4581","LU1057294990.SGD","LU0234572021.USD","SGXZ57979304.SGD","BK4550","BK4592","BK4534","LU0306806265.USD","LU1894683264.USD","LU0321505439.SGD","LU1894683348.USD","IE00B19Z3581.USD","LU0170899867.USD","BK4568","SG9999001176.USD","LU0122379950.USD","LU1066051498.USD","SG9999001176.SGD","BK4588"],"gpt_icon":1},{"id":"2516253679","title":"Lakeland Fire + Safety to Attend the 37th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516253679","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516253679?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:31","pubTimestamp":1741095060,"startTime":"0","endTime":"0","summary":"Company to Participate in a Panel Discussion March 17 and a Hosted Fireside Chat March 18. HUNTSVILLE, Ala., March 04, 2025  -- Lakeland Industries, Inc.  , a leading global manufacturer of protective clothing for industry, healthcare, and first responders, today announced that management will attend the 37th Annual Roth Conference being held at The Laguna Cliffs Marriott Resort & Spa in Dana Point, CA March 16-18, 2025.37th Annual Roth Conference Date: March 16-18, 2025Location: The Laguna Cliffs Marriott Resort & Spa, Dana Point, CAFormat: In-person 1x1 MeetingsAttendees: Chief Executive Officer and Executive Chairman Jim Jenkins and Chief Financial Officer Roger ShannonConference Website: Click here. Fireside ChatDate: Tuesday, March 18, 2025Time: 9:30 AM PTLocation: GREEN – DANA 6Participants: Chief Executive Officer and Executive Chairman Jim Jenkins and Chief Financial Officer Roger ShannonWebcast: Click here. For more information about the 37th Annual Roth Conference, or to sche","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lakeland-fire-safety-attend-37th-133100660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","BK4568","IE00B19Z4B17.USD","LAKE","BK4202","IE00B7SZL793.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2516676930","title":"Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516676930?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:15","pubTimestamp":1741094114,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nAZN3HPGL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BKVL7J92.USD","BK4550","IE0002270589.USD","IE00B7SZLL34.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4588","LU0289739699.SGD","LU1066053197.SGD","BK4139","IE00B3T34201.USD","LU0889565916.HKD","BK4566","BK4532","IE00B19Z3581.USD","LU0109394709.USD","LU0234570918.USD","LU1066051498.USD","BK4585","LU2087621335.USD","LU1585245621.USD","IE00B19Z3B42.SGD","BK4568","LU0058720904.USD","LU1430594728.SGD","BK4578","BK4583","LU1571399168.USD","LU1839511570.USD","IE00BSNM7G36.USD","GILD","LU2089984988.USD","LU2468319806.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":21,"pageCount":12,"totalSize":321}]}}